Raymond James Upgrades Revolution Medicines to Strong Buy, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Laura Prendergast upgraded Revolution Medicines (RVMD) from Outperform to Strong Buy and increased the price target from $36 to $48.
April 10, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revolution Medicines was upgraded by Raymond James from Outperform to Strong Buy, with the price target raised from $36 to $48.
Upgrades by prominent financial analysts, especially to a Strong Buy rating, typically lead to positive short-term price movements. The significant increase in the price target from $36 to $48 indicates a strong conviction in the company's future performance, likely influencing investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100